Sign in Subscribe
Diseases

Standardizing In Vitro Models to Investigate Parkinson's Disease

Strategic Insights

— 1 min read

A recent study by the PD-AGE consortium addresses the need for standardized methods in in vitro modeling to study Parkinson's disease. The research, led by experts from the University of Sheffield, highlights the importance of human induced pluripotent stem cell (iPSC)-derived models and chemically induced aging methods to replicate the disease's progression. The study emphasizes the value of direct and semi-direct reprogramming for retaining donor-specific aging phenotypes and provides a framework for measuring key measurable aging parameters.

Key Takeaways:

  • The PD-AGE consortium's position paper emphasizes the urgent need for standardizing methods in in vitro modeling to study Parkinson's disease.
  • A panel of international experts recommends using human induced pluripotent stem cell (iPSC)-derived models with chemically induced aging methods, such as the SLO cocktail, as a robust system.
  • The consortium highlights the value of direct and semi-direct reprogramming for retaining donor-specific aging phenotypes.
  • The study provides a prioritized panel of measurable parameters, including senescence, inflammaging, omics profiling, and mitochondrial dysfunction, to enhance research reproducibility.
  • The PD-AGE network has developed SOPs (https://doi-org.sdpl.idm.oclc.org/10.5281/zenodo.15056603) to measure key measurable aging parameters, facilitating consistency and reproducibility within the field.
  • The study includes a collaborative output from the PD-AGE consortium, a group of international experts in Parkinson's disease research.
  • The research received financial support from the Michael J. Fox Foundation for Parkinson's Research.

Statistics:

  • Parkinson's disease affects approximately 10 million people worldwide, with 1 in 500 people developing the disease.
  • The average age of onset for Parkinson's disease is 60-70 years.
  • 10-20% of patients with parkinsonism develop dementia within 5 years of their motor symptoms.
  • The PD-AGE consortium is a collaborative effort between international experts in Parkinson's disease research.
  • The consortium has developed a framework for measuring key measurable aging parameters to enhance research reproducibility.

Sources:

  • Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network. npj Parkinson's Disease, 2025;11(1):289.
  • NewsRx. Recent Studies from University of Sheffield Add New Data to Parkinson's Disease (Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network). Health & Medicine Week. October 24, 2025; p 4157.

Read more